Breaking the cycle: immune complexes, complement activation, and novel immunotherapies in lupus nephritis

Area of Science:

• Nephrology
• Immunology
• Rheumatology

Background:

• Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), characterized by immune complex deposition, complement activation, and podocyte injury.
• Podocytes play an active role in renal immunity, influencing disease progression through cytokine secretion and antigen presentation.

Purpose of the Study:

• To review current immunological insights into lupus nephritis pathogenesis.
• To highlight innovations in urinary biomarkers for disease monitoring.
• To summarize advancements in immunotherapy strategies for lupus nephritis.

Main Methods:

• Literature review of recent immunological findings, biomarker studies, and clinical trials in lupus nephritis.
• Analysis of the role of podocytes in renal immune modulation.
• Evaluation of novel targeted therapies and composite indices.

Main Results:

• Urinary biomarkers (NGAL, TWEAK, MCP-1) and composite indices (RAIL) enable noninvasive monitoring of LN activity.
• Targeted biologics (belimumab, telitacicept) targeting B-cell function improve outcomes.
• Emerging therapies (bortezomib, daratumumab) show efficacy in refractory cases via plasma cell depletion.

Conclusions:

• Understanding podocyte-immune interactions is crucial for LN pathogenesis.
• Biomarker and immunotherapy advancements support precision medicine approaches.
• Targeted strategies aim to improve long-term renal prognosis in lupus nephritis patients.